227 filings
Page 4 of 12
8-K
kkbk0
5 Jan 21
Other Events
4:01pm
8-K
9iskp3o iuhx7t
29 Oct 20
Regulation FD Disclosure
5:19pm
8-K
6gor2g9e
27 Oct 20
NeoGenomics Reports Revenue Growth of 20% to Record $125 Million
7:59am
8-K
wu5ruuty0a2hqd3m01
31 Jul 20
INVESTOR PRESENTATION July 2020
5:10pm
8-K
ywqo38j1mya fbc
28 Jul 20
NeoGenomics Reports Revenue of $87 Million
8:18am
8-K
5fvlh
20 Jul 20
NeoGenomics Announces Board Appointments
5:06pm
8-K
v243tf0 gt8ddlc
23 Jun 20
Departure of Directors or Certain Officers
5:00pm
8-K
2muz2k3up2bp
3 Jun 20
Departure of Directors or Certain Officers
4:41pm
8-K
lx3h5
27 May 20
NeoGenomics Enters Strategic Collaboration with Inivata to Commercialize InVisionFirstĀ®-Lung Liquid Biopsy Test
5:08pm
8-K
mn8 kqo6h1
4 May 20
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
5:18pm
8-K
onefdv sujyvju
30 Apr 20
NeoGenomics Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
12:00am
8-K
8n1x5 q9fphm85t
28 Apr 20
NeoGenomics Reports 11% Revenue Growth to $106 Million
8:15am
8-K
6dy0 axpxsrbr5pwq
17 Apr 20
Improving Patient Care 2019 Annual Report
4:55pm
8-K
zaek8q0zbbvaa15qd384
9 Apr 20
NeoGenomics Provides COVID-19 Business Update
5:12pm
8-K
gudeq351m qtm
2 Mar 20
INVESTOR PRESENTATION February 2020
5:19pm
8-K
hkn9at0
27 Feb 20
NeoGenomics Reports 40% Revenue Growth to $107 Million
8:09am
8-K
2gaa 9nc89nss980pasx
11 Feb 20
Departure of Directors or Certain Officers
5:06pm
8-K
8e3llcyn0 50wvxmsv63
13 Jan 20
NeoGenomics Acquires Oncology Division from Human Longevity for $37 Million
4:50pm
8-K
s63recsy
2 Dec 19
Departure of Directors or Certain Officers
5:07pm
8-K
diab9
31 Oct 19
INVESTOR PRESENTATION October 2019
12:00am